BaseLaunch is the Basel-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. It serves as a growth platform for early-stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A funding, providing financing and supporting all aspects of company creation and growth. It is operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency helping companies, institutions and startups find business success in the Basel area. BaseLaunch partners with leading global pharma and biotech companies and a venture fund – AbbVie, Roche, Novo Nordisk, Johnson & Johnson, CSL, Pureos Bioventures, Bridge Biotherapeutics and CMS, which also feed into the pool out of which BaseLaunch funds ventures. Domain and regional partners include KPMG, Vossius & Partner, Alloy Therapeutics, Walder Wyss attorneys at law, WuXi AppTec, KPBMA, Lonza, Charles River Laboratories, Schrödinger, Wuxi Biologics, VISCHER as well as the Tech Park Basel, and the Switzerland Innovation Park Basel Area. Since 2018, BaseLaunch supported ventures have raised in total over US$ 600 million. Harnessing the Basel area’s unique position as a global life sciences hub, as well as its rising popularity among investors, BaseLaunch is looking to attract the next generation of breakthrough companies. Interested groups can find more information at www.baselaunch.ch
Externer Link zu BaseLaunch
Dufourstrasse 11
Basel, BS 4010, CH
BaseLaunch hat dies direkt geteilt
We’re pleased to welcome Hoffmann & Partner as our new domain partner. With their strong expertise in mergers & acquisitions (M&A) and CFO services, they're an excellent addition to our collaborative network. We look forward to a successful partnership. 👉 Read more: https://lnkd.in/eVyEQFtR Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #Innovation #LifeSciences #Startups #Partnership
We’re pleased to welcome Hoffmann & Partner as our new domain partner. With their strong expertise in mergers & acquisitions (M&A) and CFO services, they're an excellent addition to our collaborative network. We look forward to a successful partnership. 👉 Read more: https://lnkd.in/eVyEQFtR Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #Innovation #LifeSciences #Startups #Partnership
🕒 Application deadline: 4 September 🕒 The application deadline is approaching. We welcome projects at any stage - whether seed, pre-seed or early concept. Our support includes financing, access to partners, and senior drug development expertise. If you're unsure if your project is at the right stage, feel free to reach out for guidance. 👉 Apply now: https://lnkd.in/e8aP-3Z Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation
👉 ANAVEON AG, one of our portfolio company, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer Pharmaceuticals, as Chair of its Board of Directors. 👉 Read more: https://lnkd.in/eP6zneAd Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation
Happy to see some of our portfolio companies featured in this article on 18 Swiss biotech companies to watch. Congrats to Alentis Therapeutics, Engimmune Therapeutics, Synendos Therapeutics AG, and TOLREMO therapeutics! #AccelerateInBasel #Therapeutics #Biotech #Innovation
Take a look at these 18 Swiss biotech companies to keep an eye on.
Driving innovation through strategic collaborations was the topic of our event co-organized and presented by CSL leadership. The discussions focused on collaborations leading to innovations and translating groundbreaking science into biotech solutions. Insights were shared on the importance of partnerships in advancing biopharmaceutical development. It was great to see so many people attending and participating in vibrant discussions. 👉 Don't miss out on future events and sign up for our newsletter to stay informed—link in the comments. Nathan Lawless, Marco Cavallari, Michael • Larbig, MD PhD, Vicky Pirzas, Leslie Bannon, Christoph Rösli, Lars Groenke, Jasmin Joller Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation
☀️ Summer get-together lookback We were pleased to have so many experts, partners, and friends at the BaseLaunch summer get-together on Wednesday last week. It was a great day of sharing knowledge, ideas, and insights, building relationships to support biotech innovation, and enjoying some laughs together. Look back at some of the moments from the day below. 👉 See more photos on the link in the comment. Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation
NXI Therapeutics AG, our portfolio company, announces the extension of a pre-seed financing totalling to CHF 3.5 million. This financing extension comes in the run-up to a larger seed financing that the company is currently raising. Further, Patrick Burgermeister, CEO of the JFG Life Sciences Foundation, will join the company’s Board of Directors. Congratulations to NXI and welcome Patrick Burgermeister! 👉 Read more: link in the comment below Ruben Herrendorff, Rajesh Jayachandran, MD PhD, Ulf Grawunder Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta #AccelerateInBasel #Therapeutics #Biotech #Innovation
🔬 Ready to make your mark in the world of biotech? Get inspired by Thomas Baumert, professor of Medicine at the Université de Strasbourg and Inserm, the French National Institute of Health and Medical Research and founder of Alentis Therapeutics, as he shares his journey from lab to business success. Learn his 9 essential tips to turn your research into a viable biotech venture. 👉 Read the article: please find the link in the comment Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta, Raphaëlle Servant #AccelerateInBasel #Therapeutics #Biotech #Innovation
👉 Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and protected from the ADC via shielded hematopoietic stem cells (HSCs). The findings point to a novel and potentially universal approach to treating blood cancers. We congratulate the authors on their groundbreaking work. 👉 Read more: link in the comment Thomas Fuchs, Stefanie Urlinger, Lukas Jeker, Simon Garaudé, Romina Matter-Marone and the teams at Jekerlab. University of Basel, Department of Biomedicine, Versant Ventures, Markus Enzelberger, Alexander Mayweg, Stephan Emmerth, Neil Goldsmith, Martyna Wroblewska, Virginia Ballotta, Raphaëlle Servant #AccelerateInBasel #Therapeutics #Biotech #Innovation